What is the share price of Astal Laboratories Ltd (ASTALLTD) today?
The share price of ASTALLTD as on 27th June 2025 is ₹82.10. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Astal Laboratories Ltd (ASTALLTD) share?
The past returns of Astal Laboratories Ltd (ASTALLTD) share are- Past 1 week: 1.09%
- Past 1 month: 1.73%
- Past 3 months: 6.74%
- Past 6 months: -1.72%
- Past 1 year: 57.60%
- Past 3 years: 190.94%
- Past 5 years: 794.34%
What are the peers or stocks similar to Astal Laboratories Ltd (ASTALLTD)?
The peers or stocks similar to Astal Laboratories Ltd (ASTALLTD) include:What is the market cap of Astal Laboratories Ltd (ASTALLTD) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Astal Laboratories Ltd (ASTALLTD) is ₹80.79 Cr as of 27th June 2025.What is the 52 week high and low of Astal Laboratories Ltd (ASTALLTD) share?
The 52-week high of Astal Laboratories Ltd (ASTALLTD) is ₹131.70 and the 52-week low is ₹52.15.What is the PE and PB ratio of Astal Laboratories Ltd (ASTALLTD) stock?
The P/E (price-to-earnings) ratio of Astal Laboratories Ltd (ASTALLTD) is 9.04. The P/B (price-to-book) ratio is 3.46.Which sector does Astal Laboratories Ltd (ASTALLTD) belong to?
Astal Laboratories Ltd (ASTALLTD) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Astal Laboratories Ltd (ASTALLTD) shares?
You can directly buy Astal Laboratories Ltd (ASTALLTD) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Astal Laboratories Ltd
ASTALLTD Share Price
82.101.38% (+1.12)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
How to use scorecard? Learn more
ASTALLTD Performance & Key Metrics
ASTALLTD Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 9.05 | 3.46 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.34 | 6.56 | 0.83% |
ASTALLTD Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
ASTALLTD Company Profile
Astal Laboratories Ltd is engaged in the pharmaceutical bulk drug business, owning a manufacturing plant for pharmaceutical intermediates in Karnataka.
SUNPHARMA
PE Ratio
37.05
37.05
1Y Return
11.30%
11.30%
Buy Reco %
87.88
87.88
CIPLA
PE Ratio
23.02
23.02
1Y Return
1.45%
1.45%
Buy Reco %
74.19
74.19
TORNTPHARM
PE Ratio
59.18
59.18
1Y Return
20.55%
20.55%
Buy Reco %
76.00
76.00
DRREDDY
PE Ratio
19.14
19.14
1Y Return
4.32%
4.32%
Buy Reco %
55.17
55.17
ZYDUSLIFE
PE Ratio
21.83
21.83
1Y Return
7.11%
7.11%
Buy Reco %
46.43
46.43
ASTALLTD Forecast
ASTALLTD Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
ASTALLTD
ASTALLTD
Income
Balance Sheet
Cash Flow
Annual Normal View
ASTALLTD Income Statement
ASTALLTD Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.31 | 0.30 | 0.30 | 0.20 | 0.20 | 0.21 | 3.61 | 23.66 | 64.36 | 64.35 | ||||||||||
Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.35 | 22.40 | 51.45 | 51.45 | ||||||||||
| Power & Fuel Cost | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 | 0.02 | 0.01 | 0.02 | ||||||||||||
| Employee Cost | 0.09 | 0.09 | 0.07 | 0.09 | 0.06 | 0.09 | 0.06 | 0.47 | ||||||||||||
| Selling & Administrative Expenses | 0.16 | 0.15 | 0.16 | 0.10 | 0.10 | 0.10 | 0.13 | 0.70 | ||||||||||||
| Operating & Other expenses | 0.01 | 0.03 | 0.11 | 0.01 | 0.01 | 0.00 | 0.01 | -1.06 | ||||||||||||
EBITDA | 0.03 | 0.01 | -0.06 | -0.02 | 0.02 | 0.00 | 0.05 | 1.13 | 12.91 | 12.90 | ||||||||||
| Depreciation/Amortization | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 | 0.03 | 0.22 | 0.22 | ||||||||||
| PBIT | 0.02 | 0.00 | -0.08 | -0.04 | 0.00 | -0.01 | 0.04 | 1.10 | 12.69 | 12.68 | ||||||||||
| Interest & Other Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.70 | 0.70 | ||||||||||
| PBT | 0.02 | 0.00 | -0.08 | -0.04 | 0.00 | -0.01 | 0.04 | 1.09 | 11.99 | 11.98 | ||||||||||
| Taxes & Other Items | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.02 | 0.30 | 3.05 | 3.05 | ||||||||||
| Net Income | 0.02 | 0.00 | -0.09 | -0.04 | 0.00 | -0.01 | 0.02 | 0.79 | 8.94 | 8.93 | ||||||||||
| EPS | 0.05 | 0.00 | -0.23 | -0.10 | 0.00 | -0.03 | 0.05 | 1.14 | 9.08 | 9.08 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
ASTALLTD Company Updates
ASTALLTD Stock Peers
ASTALLTD Past Performance & Peer Comparison
ASTALLTD Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Astal Laboratories Ltd | 9.04 | 3.46 | — |
| Sun Pharmaceutical Industries Ltd | 37.05 | 6.03 | 0.95% |
| Cipla Ltd | 23.02 | 3.88 | 1.06% |
| Torrent Pharmaceuticals Ltd | 59.18 | 16.49 | 0.96% |
ASTALLTD Stock Price Comparison
Compare ASTALLTD with any stock or ETFCompare ASTALLTD with any stock or ETF
ASTALLTD
ASTALLTD Holdings
ASTALLTD Shareholdings
ASTALLTD Promoter Holdings Trend
ASTALLTD Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
ASTALLTD Institutional Holdings Trend
ASTALLTD Institutional Holdings Trend
Increased Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has increased by 1.19%
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
ASTALLTD Shareholding Pattern
ASTALLTD Shareholding Pattern
ASTALLTD Shareholding History
ASTALLTD Shareholding History
Foreign Institutions
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing ASTALLTD stock
smallcases containing ASTALLTD stock
Looks like this stock is not in any smallcase yet.
ASTALLTD Events
ASTALLTD Events
ASTALLTD Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
ASTALLTD has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
ASTALLTD Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
ASTALLTD has not given any dividends in last 5 years
ASTALLTD Dividends
ASTALLTD Dividends
Hmm, looks like data is unavailable here. Please come back after some timeASTALLTD Stock News & Opinions
ASTALLTD Stock News & Opinions
Articles & Videos
Earnings
Astal Laboratories standalone net profit rises 389.29% in the March 2025 quarter
Net profit of Astal Laboratories rose 389.29% to Rs 2.74 crore in the quarter ended March 2025 as against Rs 0.56 crore during the previous quarter ended March 2024. Sales rose 91.59% to Rs 23.47 crore in the quarter ended March 2025 as against Rs 12.25 crore during the previous quarter ended March 2024. For the full year,net profit rose 1044.87% to Rs 8.93 crore in the year ended March 2025 as against Rs 0.78 crore during the previous year ended March 2024. Sales rose 171.59% to Rs 64.23 crore in the year ended March 2025 as against Rs 23.65 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales23.4712.25 92 64.2323.65 172 OPM %17.774.73 -19.884.69 - PBDT3.940.58 579 12.201.11 999 PBT3.840.56 586 11.981.08 1009 NP2.740.56 389 8.930.78 1045 Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Astal Laboratories to declare Quarterly Results
Astal Laboratories will hold a meeting of the Board of Directors of the Company on 19 May 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Astal Laboratories standalone net profit rises 408.16% in the December 2024 quarter
Net profit of Astal Laboratories rose 408.16% to Rs 2.49 crore in the quarter ended December 2024 as against Rs 0.49 crore during the previous quarter ended December 2023. Sales rose 71.94% to Rs 14.46 crore in the quarter ended December 2024 as against Rs 8.41 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales14.468.41 72 OPM %22.965.95 - PBDT3.100.50 520 PBT3.020.49 516 NP2.490.49 408 Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Astal Laboratories to convene board meeting
Astal Laboratories will hold a meeting of the Board of Directors of the Company on 27 January 2025.Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Astal Laboratories schedules board meeting
Astal Laboratories will hold a meeting of the Board of Directors of the Company on 27 November 2024Powered by Capital Market - Live
7 months agoCapital Market - Live
Earnings
Astal Laboratories standalone net profit rises 257.14% in the September 2024 quarter
Net profit of Astal Laboratories rose 257.14% to Rs 2.00 crore in the quarter ended September 2024 as against Rs 0.56 crore during the previous quarter ended September 2023. Sales rose 7.43% to Rs 13.16 crore in the quarter ended September 2024 as against Rs 12.25 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales13.1612.25 7 OPM %21.964.73 - PBDT2.800.58 383 PBT2.770.56 395 NP2.000.56 257 Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Astal Laboratories to hold board meeting
Astal Laboratories will hold a meeting of the Board of Directors of the Company on 12 November 2024Powered by Capital Market - Live
7 months agoCapital Market - Live
Earnings
Astal Laboratories standalone net profit rises 16800.00% in the June 2024 quarter
Net profit of Astal Laboratories rose 16800.00% to Rs 1.69 crore in the quarter ended June 2024 as against Rs 0.01 crore during the previous quarter ended June 2023. Sales rose 866.91% to Rs 13.15 crore in the quarter ended June 2024 as against Rs 1.36 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales13.151.36 867 OPM %18.100 - PBDT2.350.01 23400 PBT2.340.01 23300 NP1.690.01 16800 Powered by Capital Market - Live
11 months agoCapital Market - Live
Macro International reports standalone net loss of Rs 0.01 crore in the September 2021 quarter
3 years agoBusiness Standard
Over the last 5 years, revenue has grown at a yearly rate of 139.54%, vs industry avg of 9.02%
Over the last 5 years, market share increased from 0% to 0.01%